UnitedHealth Group's decision to raise its 2026 guidance prompted a broad pre-market rise in managed care stocks on Thursday, buoying several of the industry's largest names.
CVS Health (NYSE:CVS) rose about 1.8% in early trading. Centene (NYSE:CNC) and Molina Healthcare (NYSE:MOH) advanced roughly 3.5% and 3.6%, respectively. Humana's shares increased by nearly 5%, while Elevance Health climbed around 2.5%.
The movement followed UnitedHealth's updated full-year adjusted earnings guidance of $19.50 to $20.00 per share, an increase from its prior guidance of above $18.25 and ahead of the average analyst estimate of $18.43. The company also provided a separate EPS projection range of $18.45 to $18.95, compared with its earlier outlook of above $17.35.
UnitedHealth reported second-quarter adjusted earnings per share of $6.38, up from $4.08 a year earlier and exceeding the consensus estimate of $4.89. Quarterly revenue totaled $112.03 billion, a 0.4% increase from the year-ago period and higher than the consensus estimate of $110.67 billion.
Management cited an 86.7% medical care ratio (MCR), attributing improvement to product design changes, enhanced medical management and more closely aligned pricing. The company said the MCR was affected by $860 million of net favorable prior-period development, with the bulk of that related to 2026 dates of service.
Investors interpreted UnitedHealth's stronger outlook and quarterly performance as a sign of improving conditions within the managed care segment, which in turn supported share gains at competing insurers. The reported figures combine a beat on earnings and revenue with margin-related commentary tied to both operational changes and accounting for prior-period items.
Key takeaways
- UnitedHealth raised its full-year adjusted EPS guidance to $19.50-$20.00, topping analyst expectations and its previous outlook.
- Second-quarter adjusted EPS of $6.38 and revenue of $112.03 billion both exceeded estimates, with revenue up 0.4% year-over-year.
- Sector peers reacted positively in pre-market trading, with Humana, Centene, Molina, CVS and Elevance all recording notable gains.
Risks and uncertainties
- The medical care ratio was materially influenced by $860 million of net favorable prior-period development, an accounting item that affected reported margins.
- Revenue growth in the quarter was modest at 0.4% year-over-year, indicating limited top-line expansion despite the earnings beat.
- Guidance is presented as ranges and remains subject to change; the company provided two different EPS range statements versus prior outlooks, reflecting updates but also variability in forward estimates.